A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Bristol-Myers Squibb
Study ID
NCT03251924
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

  • Cancer
  • Malignancy
  • Neoplasm
  • Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986226 — DRUG
    specified dose on specified days
  • Nivolumab — BIOLOGICAL
    specified dose on specified days
  • Ipilimumab — BIOLOGICAL
    specified dose on specified days
  • Tetanus Vaccine — BIOLOGICAL
    specified dose on specified days

Study Details

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

Key Dates

Start date
Sep 1, 2017
Status verified
Jan 2023
Primary completion
Dec 20, 2021
Completion
Dec 20, 2021

Study Design

Enrollment
80 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: BMS-986226
    administered intravenously
  • Experimental: BMS-986226 and Nivolumab
    administered intravenously
  • Experimental: BMS-986226 and Ipilimumab
    administered intravenously

Primary Outcome Measure

The Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: From first dose up to 100 days post last dose, up to approximately 31 months ]

Locations (5)

FacilityCityStateZIPSite coordinators
Local Institution - 0005BostonMassachusetts02215-
Local Institution - 0012St LouisMissouri63110-
Local Institution - 0002HackensackNew Jersey07601-
Local Institution - 0001PhiladelphiaPennsylvania19111-
Local Institution - 0004NashvilleTennessee37203-

Find similar trials in Boston, MA

By research site
Local Institution - 0005· Boston, MALocal Institution - 0012· St Louis, MOLocal Institution - 0002· Hackensack, NJLocal Institution - 0001· Philadelphia, PALocal Institution - 0004· Nashville, TN

Related Studies